Exercise Intervention to Reduce Adverse Quality of Life Effects From Androgen Deprivation Therapy for Prostate Cancer - Randomized Clinical Trial
Phase: NA
Conditions: Prostate Cancer
Sponsor: Tampere University Hospital

Exercise and quality of life during 
androgen deprivation therapy – a 
randomized trial 
 
Short title: Patient school 1 
 
Lauri Rantaniemi1, Jarno Riikonen2, Hanna Ojala3, Ilkka Pietilä3, Teuvo L.J. Tammela1,2, Teemu J. Murtola1,2 
 
1. Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland 
2. Tampere University Hospital, Department of Urology, Tampere, Finland  
3. Tampere University, Faculty of Social Sciences, Tampere, Finland 
1 BACKGROUND 
Prostate cancer is the most common non-cutanoeus cancer and among the top three causes of cancer 
deaths among men in Finland and other Western countries. Burden of health care costs due to the 
condition rise up to 180 million euros/year in Finland (1).  
Androgens are vital for prostate cancer progression, and androgen deprivation therapy is cornerstone in 
management of advanced or recurrent prostate cancer that is beyond curative treatment. In androgen 
deprivation therapy (ADT) serum testosterone is lowered either medically or surgically to a level lower than 
1,72 µmol/l (50 ng/dl). (2) These prevents activation of androgen receptors in prostate cancer cells, leading 
to involution of the prostate tumor and metastases, decreased proliferation and increased apoptosis of 
prostate cancer cells (3,4). 
Common side effects of ADT include fatigue, weight gain, muscle loss, decreased libido and erectile 
dysfunction, amounting to decreased quality of life (5). Low serum testosterone has also been linked with 
increased risk for type II diabetes and metabolic syndrome (6). Also associations with elevated risk for 
memory impairment and cardiovascular disease have been proposed (7,8). 
Systematic review published in 2012 found strong evidence for improved overall quality of life among ADT-
treated prostate cancer patients participating in supervised resistance training. Moderate evidence was 
found also for improved physical and social well-being. The authors recommended exercise for all prostate 
cancer patients on ADT and called for further studies comparing supervised and unsupervised exercise (9). 
A recent randomized trial found equal fatigue reduction and vitality increase both with supervised and 
unsupervised exercise (10). 

2 STUDY GOALS 
The study compares effects of supervised and unsupervised exercise on plasma lipid parameters (total 
cholesterol, LDL, HDL and triglycerides) and glucose levels (fasting plasma glucose, glycated hemoglobin), 
overall quality of life and on average daily exercise activity in men with prostate cancer and under ADT. As 
secondary outcome we will study effect on continued exercise activity after the intervention, changes in 
body composition, blood pressure and risk of fractures, castration resistance as well as death due to 
prostate cancer and due to any cause.  
Study hypothesis is that supervised exercise will improve quality of life, lipid and glucose parameters and 
increase daily exercise activity more that non-supervised exercise. We also expect higher continued 
exercise activity, greater changes in body composition and blood pressure and lowered risk of fractures and 
death in the supervised exercise group.     
3 STUDY SETTING 
This is a randomized, controlled clinical trial. The study aims to recruit 40 men on ADT for prostate cancer. 
This will be a pilot study to estimate effect sizes in Finnish population to inform further larger trial. For this 
reason the sample size will be smaller compared to previous studies on the topic (10,11) and no power 
calculation is performed yet. 
 
 

Figure: Study flow chart 
 
 
← 2. qualitative 
interview (5 men) 
2. qualitative 
interview (5 
men) → 
← 3. qualitative 
interview (5 
men) and group 
interview (all 
men)
3. qualitative 
interview (5 
men) and group 
interview (all 
men) → 
← 1. qualitative interview (10 men) 
1. follow-up 
--blood tests 
-EORTC quality of life surveys 
-body composition 
2. follow-up 
--blood tests 
-EORTC quality of life surveys 
-body composition 
12 wks of superv.exercise 
1. follow-up 
--blood tests 
-EORTC quality of life surveys 
-body composition 
-blood tests 
-EORTC quality of life surveys 
-body composition 
Non-supervised 
exercise (20 men) 
-blood tests 
-EORTC quality of life surveys 
-body composition 
Supervised exercise 
(20 men) 
Randomization 
Recruitment (40 men)
Exclusions 
-high risk of fracture 
-ECOG ≥ 2 
-Non-Finnish speaking 
Introductory lecture  
2. follow-up 
--blood tests 
-EORTC quality of life surveys 
-body composition 
Long-term follow-up 
12 wks of non-superv.exercise 
12 wks of non-superv.exercise 
12 wks of non-superv.exercise 

4 INCLUSION- AND EXCLUSION CRITERIA 
Inclusion criteria: 
- 
ADT for prostate cancer, regardless of treatment duration  
- 
Willingness to participate in the study; signing of informed consent 
Exclusion criteria: 
- 
Unability for physical exertion; ECOG 2 or higher 
- 
High risk for bone fractures as evaluated by the attending clinician  
- 
Non-Finnish speaking; unability to comprehend Finnish 
5 INTERVENTION 
All participants attend introductory lecture, where a urologist informs them about adverse effects of ADT 
and positive effects of exercise during ADT, exercise instructor gives advice for training both at home and in 
the gym and nutritional therapeutist tells about nutrition to overcome adverse effects of ADT and support 
training. 
After the introductory lecture tha participants are randomized 1:1 to either the supervised or non-
supervised exercise group (Figure). Men in the supervised group participate in progressive group exercise 
sessions twice a week for total of 12 weeks at the Varala sports academy in Tampere, Finland. Each exercise 
session includes both aerobic and resistance training targeting all major muscle groups (Additional 
document I, exercise program). The non-supervised group will exercise independently for 12 weeks 
according to the instructions given at the introductory lecture. The first control visit will be after this first 
period of 12 weeks of exercise. 
After the first follow-up visit both group will continue non-supervised exercise for 12 weeks, after which the 
second control visit will be arranged. Special focus on the second control visit is to see how many in each 
group has been able to carry on active exercising, i.e. has the intervention promoted long-term change in 
exercise activity.  
Both study group will be given Polar wrist activity monitors to be used 24 h/day for the entire course of the 
study. 
All participants are asked to fill validated quality of life surveys EORTC QLQC-30 (overall quality of life) and 
EORTC QLQC-PR25 (prostate cancer-specific quality of life) at baseline and again at 1st and 2nd control 
visits. Plasma lipid and glucose parameters, blood pressure and body composition wll be measured at each 
of these visits. 
At each visit a separate blood sample is taken and stored for future measurement of biomarkers associated 
with prostate cancer progression, glucose and lipid metabolism and effects of exercise.  
6 QUALITATIVE EVALUATION OF SUBJECTIVE CAPABILITIES AND QUALITY OF LIFE 
On each visit a qualitative evaluation will be performed based on individual- and group interviews to 
evaluate how men find ADT and exercise affecting their quality of life and how they perceive the 
intervention as a means to increase their physical activity. On the interviews information will be collected 
on:  

1. How men on ADT perceive their quality of life and what is their subjective definition of quality of life? 
- 
What kind of side-effects they have had from ADT, how they cope with them in everyday life and 
how cancer, ADT and ADT side-effects have affected their quality of life? 
- 
What role exercise has had in their lives before prostate cancer and after it, and how the amount of 
exercise is tied to their perceived quality of life? 
 
2. What kind of opportunities and obstacles of exercise the participants find in their lives? 
- 
How men in the supervised exercise group think the intervention will affect their exercise activity in 
the future? Can supervised exercise help to overcome obstacles for exercising? 
- 
How men in the non-supervised exercise group cope with obstacles for exercise? 
 
Baseline interveiw, before the study randomization: A group of 10 men are interviewed before randozation 
to the exercise groups. The goal is to find how participants expect the intervention to affect their activity 
and quality of life before they know in which group they will participate. 
Second interview at the first control visit:  Men in the supervised exercise group are interviewed about the 
role of their group and supervision on their exercise activity and perceived quality of life. Non-supervised 
group is interviewed how they have managed to follow the given exercise program and how ot has affected 
their quality of life. All men are asked how they think they exercise habits would have differed had they 
been randomized to the other intervention group. Additionally their views about how they will be able to 
carry on exercising will be asked.  
Third interview at the second control visit: The questions will evaluate how men have carried on with the 
exercise; have they been able to increase it or has it rather decreased; have the men found that the 
exercise intervention has affected their quality of life. 
 
7 STUDY OUTCOMES AND STATISTICAL ANALYSIS 
Primary outcomes: 
- 
Daily total activity, measured during the entrie course of study with wrist activity monitor in 
metabolic equivalents of task (MET) units 
- 
Fasting plasma cholesterol, LDL, HDL and triglycerides, measured at baseline and again at the 1st 
and 2nd control visits 
- 
Fasting plasma glucose and glycated haemoglobin (HbA1C), measured at baseline and again at the 
1st and 2nd control visits  
- 
Overall quality of life and prostate cancer-specific quality of life, measured with validated Finnish 
versions of EORTC QLQC-30 v.3.0 ja EORTC QLQ-PR25 at baseline and at each control visit 
 
Seconday outcomes: 
- 
Change in daily activity after the end of supervised group exercise intervention; difference 
compared to the non-supervised group. Measured with wrist activity monitor in MET units 
- 
Body mass composition, bioimpedance-based measurement of lean body mass, fat mass and 
skeletal mass as percentage of total body mass measured with TANITA MC-780 device 

- 
Blood pressure level, measured at baseline and each control visit 
- 
Subjective effect of exercise on quality of life and perceived adverse effects of ADT, as based on 
qualitative interviews 
 
Long-term follow-up 
The participants are followed via patient files and national health care registries. Outcomes to be followed 
are: 
- 
Time from baseline to castration resistance (progression of prostate cancer despite ADT as 
evidenced by constantly rising PSA or radiological disease progression) 
- 
Bone fractures 
- 
Diagnosis of memory impairment 
- 
Diagnosis of diabetes mellitus 
- 
Diagnosis of cardiovascular disease 
- 
Prostate cancer death 
- 
Death due to any causei 
 
Statistical analysis 
 
All comparisons are done between the supervised and non-supervised exercise arms. Medians of daily 
activity (in MET units) and quantitative quality of life (as points from the EORTC surveys) at baseline and at 
each control visit are compared with either Mann-Whitney U-test or Student’s t-test depending on 
normality of the data distribution. Difference in medians of plasma lipid parameters and glucose 
parameters are analyzed similarly. 
Of the secondary outcomes median time to castration resistance and death are compared between the trail 
arms using Kaplan-Meier analysis and log-rank test. Analysis for risks of castration resistance, death, 
prostate cancer death, cardiovascular disease, bone fracture and memory impairment will be analysed 
using Cox regression with months from the study randomization as the time metric. The regression model 
will be adjusted for the study arm, age at baseline, time between prostate cancer diagnosis and 
randomization, ADT method and the time on ADT before participating in the trial. 
 
8 ETHICAL CONSIDERATIONS 
8.1 BENEFITS AND RISK OF HARM FOR THE PARTICIPANTS 
 
Evidence for quality of life improvement due to exercise is strong, and therefore the participants likely 
benefit from the study participation in both study arms. Participating in an exercise program increases risk 
of musculoskeletal injuries and possibly cardiovascular events. Such risks are minimized by selecting 
participants with adequate physical condition and tailoring the research program according to individual 
performance level.   

8.2 FUNDING 
 
Astellas Pharma funds the group exercise sessions during the study, but does not otherwise participate in 
the design or conduct of the study, data analysis, writing of results nor in the decision to publish the results. 
Clinical trial will be funded with grants from commercially independent sources, such as Pirkanmaa Hospital 
District. 
8.3 CONFLICTS OF INTEREST 
 
LR: None 
JR: Congress participation at the expense of Astellas and Ferring. Consulting fees from: Astellas, Ferring, 
Pfizer, Bayer, Lidds, Myovant. 
HO: None 
IP: None. 
TLJT: Consulting fees from: Astellas Pharma, Orion Pharma and Bayer AG. 
TJM: Lecture fees from: Astellas Pharma, Jansen and MSD. Consutling fees from: Astellas Pharma and 
Janssen.  
9 REFERENCES 
1. Mäklin S, Rissanen P. Syöpien aiheuttamat kustannukset. Syöpäjärjestöjen julkaisuja nro 67, 2006. 
Luettavissa 
osoitteessa: 
http://www.cancer.fi/@Bin/1697304/Syöpien+aiheuttamat+kustannukset.pdf  
2. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, 
Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van 
der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P: EAU-ESTRO-SIOG 
Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative 
Intent. Eur Urol 2017, 71(4):618-629. 
3. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and 
androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 
1972 Jul-Aug;22(4):232-40. 
4. Culig, Z. & Santer, F.R. Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev (2014) 
33: 413. doi:10.1007/s10555-013-9474-0 
5. Rowan G Casey, Niall M Corcoran, and S Larry Goldenberg. Quality of life issues in men undergoing 
androgen deprivation therapy: a review. Asian J Androl. 2012 Mar; 14(2): 226–231. 
6. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nature reviews 
Endocrinology. 2009;5:673–681. 
7. Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, 
Montorsi F, Karakiewicz PI. The impact of androgen-deprivation therapy (ADT) on the risk of 
cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based 
study. BJU Int. 2014 Dec;114(6b):E82-9. doi: 10.1111/bju.12732 

8. Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association Between 
Androgen Deprivation Therapy and Risk of Dementia. JAMA Oncol. 2017 Jan 1;3(1):49-55. doi: 
10.1001/jamaoncol.2016.3662. 
9. Keogh JW, MacLeod RD. Body composition, physical fitness, functional performance, quality of life, 
and fatigue benefits of exercise for prostate cancer patients: a systematic review. J Pain Symptom 
Manage. 2012 Jan;43(1):96-110. doi: 10.1016/j.jpainsymman.2011.03.006. 
10. Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, Wall BA, Cormie P8, Bolam KA, 
Galvão DA. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing 
Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial. Eur Urol. 2017 Feb 26. doi: 
10.1016/j.eururo.2017.02.019 
 
 

11. Peter Østergren, Anne-Mette Ragle, Henrik Jakobsen, Tobias Wirenfeldt Klausen, Anders Vinther, 
Jens Sønksen. Group-based exercise in daily clinical practice to improve physical fitness in men with 
prostate cancer undergoing androgen deprivation therapy: study protocol. BMJ Open. 
2016;6:e011460. doi:10.1136/bmjopen-2016-011460

10 ADDITIONAL DOCUMENTS 
Additional document I: 
Exercise program 
 

 
Nimi:  
 
 
Viikko 1 
Viikko 2 
Viikko 3 
Viikko 4 
 
Säädöt 
d.  
d.  
d.  
d.  
d.  
d.  
d.  
d.  
1 Alasoutu  
 
Istuin: 
 
 
 
Rintatuki: 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
2 Reisiojennus  
 
Istuin: 
 
Kahva: 
 
 
Nilkkatyy
ny: 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
3 Rintaprässi
 
Istuin:  
 
 
Kahva: 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  

 
4 Vatsarutistus 
 
 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
 
 
d.  
d.  
d.  
d.  
d.  
d.  
d.  
d.  
5 Reisikoukistus 
 
Istuin: 
 
Kahva: 
 
 
Nilkkatyy
ny: 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  

6 Selkäojennus 
 
Nakke-
pude: 
 
Kahva: 
 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
7 Jalkaprässi
 
Istuin: 
 
Sarjat: 
15-15 
Kg:  
Sarjat: 
15-15 
Kg:  
Sarjat: 
12-12 
Kg: 
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Kuntopyörä 
 
Istuin: 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Crosstrainer 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Porrasnousu 
 
Aika: 
Korkeus: 
 
 
 
 
 
 
 
 
Juoksumatto 
 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Soutulaite 
 
Aika: 
Matka: 
 
 
 
 
 
 
 
 

 
 
 
Lankku 
 
Aika: 
 
 
 
 
 
 
 
 

 
Nimi:  
 
 
Viikko 5 
Viikko 6 
Viikko 7 
Viikko 8 
 
 
d.  
d.  
d.  
d.  
d.  
d.  
d.  
d.  
1 Alasoutu 
 
Istuin: 
 
 
 
Rintatuki: 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
2 Reisiojennus 
 
Istuin: 
 
Kahva: 
 
 
Nilkkatyy
ny: 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
3 Rintaprässi
 
Istuin:  
 
 
Kahva: 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  

 
4 Vatsarutistus 
 
 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
 
 
d.  
d.  
d.  
d.  
d.  
d.  
d.  
d.  
5 
Reisikoukistus 
 
Istuin: 
 
Kahva: 
 
 
Nilkkatyy
ny: 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  

6 Selkäojennus 
 
Kahva: 
 
 
Nakke-
pude: 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
7 Jalkaprässi
 
Istuin: 
 
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg:  
Sarjat: 
12-12-12 
Kg: 
Sarjat  
12-12-12 
Kg:  
Sarjat  
12-12-12 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Kuntopyörä 
 
Istuin: 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Crosstrainer 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Porrasnousu 
 
Aika: 
Korkeus: 
 
 
 
 
 
 
 
 
Juoksumatto 
 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Soutulaite 
 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Lankku 
Aika: 
 
 
 
 
 
 
 
 

 
 
 
 

 
Nimi:  
 
 
Viikko 9 
Viikko 10 
Viikko 11 
Viikko 12 
 
 
d.  
d.  
d. 
d.  
d.  
d. (st) 
d. (fw) 
d. (fw) 
1 Alasoutu 
 
Istuin: 
 
 
 
Rintatuki: 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
2 Reisiojennus 
 
Istuin: 
 
Kahva: 
 
 
Nilkkatyy
ny: 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
3 Rintaprässi
 
Istuin:  
 
 
Kahva: 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  

 
4 Vatsarutistus 
 
 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
 
 
d.  
d.  
d. 
d.  
d.  
d. (st) 
d. (fw) 
d. (fw) 
5 
Reisikoukistus 
 
Istuin: 
 
Kahva: 
 
 
Nilkkatyy
ny: 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  

 
6 Selkäojennus 
 
Kahva: 
 
 
Nakke-
pude: 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
7 Jalkaprässi
 
Istuin: 
 
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg:  
Sarjat: 
10-10-10 
Kg: 
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Sarjat  
10-10-10 
Kg:  
Kuntopyörä 
 
Istuin: 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Aika/km 
Crosstrainer 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Porrasnousu 
 
Aika: 
Korkeus: 
 
 
 
 
 
 
 
 
Juoksumatto 
 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Soutulaite 
 
Aika: 
Matka: 
 
 
 
 
 
 
 
 
Lankku 
Aika: